MedTrace Logo

Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

NCT05248919 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2025-11-21

No results posted yet for this study

Summary

This trial is linked to a largescale observational study determining the efficacy of sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The observational study will identify a cohort of patients who have not responded to first-line antiviral therapy (sofosbuvir plus daclatasvir) and the optimal treatment for these patients is unclear. This trial will address this issue by comparing two second-line treatment regimens to determine the preferred treatment option.

Conditions

  • Hepatitis C

Interventions

DRUG

Epclusa (nucleotide HCV NS5B polymerase inhibitors).

Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks

Sponsors & Collaborators

  • Aga Khan University

    collaborator OTHER

  • Dow University of Health Sciences

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Bristol

    collaborator OTHER

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Graham Foster, MBBS · Queen Mary University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2027-09-01
Completion
2027-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05248919 on ClinicalTrials.gov